Market Analysis and Insights: Global AntiParkinson Drugs Market
The global AntiParkinson Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global AntiParkinson Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global AntiParkinson Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global AntiParkinson Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global AntiParkinson Drugs market.
Global AntiParkinson Drugs Scope and Market Size
Anti-Parkinson Drugs market is segmented
by players, region (country),
by Type and
by Application. Players, stakeholders, and other participants in the global Anti-Parkinson Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast
by Type and
by Application for the period 2018-2032.
Segment by Type
- Dopaminergic
- Dopamine Agonists
- Enzyme Inhibitors
- Others
Segment by Application
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
By Company
- AbbVie
- Mylan Laboratories
- Valeant Pharmaceuticals
- Novartis
- GlaxoSmithKline
- Zambon Pharmaceuticals
- Pfizer, Inc.
- Hoffmann-La Roche
- Merck & Co.
- Orion Pharma
- UCB
- Teva Pharmaceutical Industries Ltd.
- Vertical Pharmaceuticals, LLC
- ACADIA Pharmaceuticals Inc.
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes AntiParkinson Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of AntiParkinson Drugs, with price, sales, revenue, and global market share of AntiParkinson Drugs from 2019 to 2022.
Chapter 3, the AntiParkinson Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the AntiParkinson Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the AntiParkinson Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of AntiParkinson Drugs.
Chapter 13, 14, and 15, to describe AntiParkinson Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 AntiParkinson Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2018-2032)
2.2 Anti-Parkinson Drugs Growth Trends by Region
2.2.1 Anti-Parkinson Drugs Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2018-2023)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2023-2032)
2.3 Anti-Parkinson Drugs Market Dynamics
2.3.1 Anti-Parkinson Drugs Industry Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2018-2023)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2022
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2018-2023)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2023-2032)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2018-2023)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2018-2032)
6.2 North America Anti-Parkinson Drugs Market Size by Country (2018-2023)
6.3 North America Anti-Parkinson Drugs Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2018-2032)
7.2 Europe Anti-Parkinson Drugs Market Size by Country (2018-2023)
7.3 Europe Anti-Parkinson Drugs Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2018-2032)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Country (2018-2023)
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2018-2032)
9.2 Latin America Anti-Parkinson Drugs Market Size by Country (2018-2023)
9.3 Latin America Anti-Parkinson Drugs Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2018-2032)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2018-2023)
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Detail
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Detail
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Detail
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Detail
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Detail
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Detail
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Detail
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Detail
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2018-2023)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Dopaminergic
Table 3. Key Players of Dopamine Agonists
Table 4. Key Players of Enzyme Inhibitors
Table 5. Key Players of Others
Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 7. Global Anti-Parkinson Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 8. Global Anti-Parkinson Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Anti-Parkinson Drugs Market Share by Region (2018-2023)
Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 11. Global Anti-Parkinson Drugs Market Share by Region (2023-2032)
Table 12. Anti-Parkinson Drugs Market Trends
Table 13. Anti-Parkinson Drugs Market Drivers
Table 14. Anti-Parkinson Drugs Market Challenges
Table 15. Anti-Parkinson Drugs Market Restraints
Table 16. Global Anti-Parkinson Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Anti-Parkinson Drugs Market Share by Players (2018-2023)
Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2022)
Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
Table 23. Date of Enter into Anti-Parkinson Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Anti-Parkinson Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2023-2032)
Table 29. Global Anti-Parkinson Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2023-2032)
Table 33. North America Anti-Parkinson Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Anti-Parkinson Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 35. Europe Anti-Parkinson Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Anti-Parkinson Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 37. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2023-2032) & (US$ Million)
Table 39. Latin America Anti-Parkinson Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 40. Latin America Anti-Parkinson Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 41. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 42. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2023-2032) & (US$ Million)
Table 43. AbbVie Company Detail
Table 44. AbbVie Business Overview
Table 45. AbbVie Anti-Parkinson Drugs Product
Table 46. AbbVie Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 47. AbbVie Recent Development
Table 48. Mylan Laboratories Company Detail
Table 49. Mylan Laboratories Business Overview
Table 50. Mylan Laboratories Anti-Parkinson Drugs Product
Table 51. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 52. Mylan Laboratories Recent Development
Table 53. Valeant Pharmaceuticals Company Detail
Table 54. Valeant Pharmaceuticals Business Overview
Table 55. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
Table 56. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 57. Valeant Pharmaceuticals Recent Development
Table 58. Novartis Company Detail
Table 59. Novartis Business Overview
Table 60. Novartis Anti-Parkinson Drugs Product
Table 61. Novartis Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. GlaxoSmithKline Company Detail
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Anti-Parkinson Drugs Product
Table 66. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 67. GlaxoSmithKline Recent Development
Table 68. Zambon Pharmaceuticals Company Detail
Table 69. Zambon Pharmaceuticals Business Overview
Table 70. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
Table 71. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 72. Zambon Pharmaceuticals Recent Development
Table 73. Pfizer, Inc. Company Detail
Table 74. Pfizer, Inc. Business Overview
Table 75. Pfizer, Inc. Anti-Parkinson Drugs Product
Table 76. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 77. Pfizer, Inc. Recent Development
Table 78. Hoffmann-La Roche Company Detail
Table 79. Hoffmann-La Roche Business Overview
Table 80. Hoffmann-La Roche Anti-Parkinson Drugs Product
Table 81. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 82. Hoffmann-La Roche Recent Development
Table 83. Merck & Co. Company Detail
Table 84. Merck & Co. Business Overview
Table 85. Merck & Co. Anti-Parkinson Drugs Product
Table 86. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 87. Merck & Co. Recent Development
Table 88. Orion Pharma Company Detail
Table 89. Orion Pharma Business Overview
Table 90. Orion Pharma Anti-Parkinson Drugs Product
Table 91. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 92. Orion Pharma Recent Development
Table 93. UCB Company Detail
Table 94. UCB Business Overview
Table 95. UCB Anti-Parkinson DrugsProduct
Table 96. UCB Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 97. UCB Recent Development
Table 98. Teva Pharmaceutical Industries Ltd. Company Detail
Table 99. Teva Pharmaceutical Industries Ltd. Business Overview
Table 100. Teva Pharmaceutical Industries Ltd. Anti-Parkinson DrugsProduct
Table 101. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 102. Teva Pharmaceutical Industries Ltd. Recent Development
Table 103. Vertical Pharmaceuticals, LLC Company Detail
Table 104. Vertical Pharmaceuticals, LLC Business Overview
Table 105. Vertical Pharmaceuticals, LLC Anti-Parkinson DrugsProduct
Table 106. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 107. Vertical Pharmaceuticals, LLC Recent Development
Table 108. ACADIA Pharmaceuticals Inc. Company Detail
Table 109. ACADIA Pharmaceuticals Inc. Business Overview
Table 110. ACADIA Pharmaceuticals Inc. Anti-Parkinson DrugsProduct
Table 111. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2018-2023) & (US$ Million)
Table 112. ACADIA Pharmaceuticals Inc. Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-Parkinson Drugs Market Share by Type: 2022 VS 2032
Figure 2. Dopaminergic Features
Figure 3. Dopamine Agonists Features
Figure 4. Enzyme Inhibitors Features
Figure 5. Others Features
Figure 6. Global Anti-Parkinson Drugs Market Share by Application in 2022 & 2032
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Stores Case Studies
Figure 10. Anti-Parkinson Drugs Report Years Considered
Figure 11. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 12. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 13. Global Anti-Parkinson Drugs Market Share by Region: 2022 VS 2032
Figure 14. Global Anti-Parkinson Drugs Market Share by Players in 2022
Figure 15. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2022
Figure 17. North America Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 18. North America Anti-Parkinson Drugs Market Share by Country (2018-2032)
Figure 19. United States Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 20. Canada Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 21. Europe Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 22. Europe Anti-Parkinson Drugs Market Share by Country (2018-2032)
Figure 23. Germany Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 24. France Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 25. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. Italy Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 27. Russia Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 28. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2018-2032)
Figure 31. China Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 32. Japan Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 33. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 35. India Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 36. Australia Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. Latin America Anti-Parkinson Drugs Market Share by Country (2018-2032)
Figure 39. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 40. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 41. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2018-2032)
Figure 43. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 44. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 45. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 46. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 47. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 48. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 50. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 51. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 52. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 53. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 54. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 55. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 56. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 57. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 58. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
